Cypress Capital’s Bristol-Myers Squibb BMY Stock Holding History

Cypress Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.58M	Sell	44,705 -1,356	-3%	-$77.9K	0.7%	31
2026 Q1	$2.79M	Buy	46,061 +8,019	+21%	+$467K	0.79%	27
2025 Q4	$2.05M	Sell	38,042 -8,350	-18%	-$402K	0.57%	40
2025 Q3	$2.09M	Sell	46,392 -1,571	-3%	-$73.4K	0.6%	40
2025 Q2	$2.22M	Sell	47,963 -104	-0.2%	-$5.11K	0.64%	35
2025 Q1	$2.93M	Buy	48,067 +479	+1%	+$27.9K	0.85%	20
2024 Q4	$2.69M	Buy	47,588 +9,693	+26%	+$542K	0.77%	22
2024 Q3	$1.96M	Buy	37,895 +3,014	+9%	+$141K	0.51%	41
2024 Q2	$1.45M	Buy	34,881 +1,234	+4%	+$55.2K	0.36%	43
2024 Q1	$1.82M	Buy	33,647 +30	+0.1%	+$1.53K	0.5%	39
2023 Q4	$1.72M	Buy	33,617 +1,124	+3%	+$59K	0.49%	41
2023 Q3	$1.89M	Sell	32,493 -598	-2%	-$36.6K	0.55%	38
2023 Q2	$2.12M	Buy	33,091 +837	+3%	+$56.1K	0.61%	34
2023 Q1	$2.24M	Buy	32,254 +858	+3%	+$60.5K	0.7%	25
2022 Q4	$2.26M	Buy	31,396 +281	+0.9%	+$21.2K	0.71%	29
2022 Q3	$2.21M	Buy	31,115 +2,273	+8%	+$165K	0.78%	19
2022 Q2	$2.22M	Buy	28,842 +1,356	+5%	+$103K	0.32%	51
2022 Q1	$2.01M	Buy	27,486 +984	+4%	+$66.1K	0.25%	67
2021 Q4	$1.65M	Buy	26,502 +852	+3%	+$50K	0.19%	89
2021 Q3	$1.52M	Buy	25,650 +2,264	+10%	+$149K	0.19%	92
2021 Q2	$1.56M	Buy	23,386 +3,286	+16%	+$214K	1.53%	24
2021 Q1	$1.27M	Buy	20,100 +1,570	+8%	+$97.7K	0.52%	43
2020 Q4	$1.15M	Sell	18,530 -204	-1%	-$12.5K	0.52%	39
2020 Q3	$1.14M	Sell	18,734 -211	-1%	-$12.7K	0.53%	35
2020 Q2	$1.11M	Buy	+18,945	New	+$1.13M	0.49%	34
2019 Q4	$1.01M	Buy	15,762 +1,046	+7%	+$59.9K	0.43%	30
2019 Q3	$746K	Buy	14,716 +1,274	+9%	+$59.9K	0.34%	50
2019 Q2	$609K	Buy	13,442 +827	+7%	+$38.5K	0.28%	56
2019 Q1	$602K	Buy	12,615 +1,279	+11%	+$63.7K	0.25%	58
2018 Q4	$589K	Buy	+11,336	New	+$609K	0.27%	43

Other funds holding BMY

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

ORIO

Old Republic International (ORI) Chicago, Illinois $2.67B AUM 26.94% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

UBP

Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return

Cypress Capital's BMY Position: Q2 2026 in Review

Cypress Capital reduced its Bristol-Myers Squibb (BMY) stake by 2.9% in Q2 2026, selling an estimated $77.9K and leaving 44,705 shares worth $2.58M. The position accounts for 0.7% of the portfolio, ranked #31.

Cypress Capital first reported a position in BMY in Q4 2018 and has held it in 30 quarters since. The position peaked at $2.93M in Q1 2025. 498 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Cypress Capital held 44,705 shares of Bristol-Myers Squibb worth $2.58M as of Q2 2026.
Cypress Capital sold 1,356 Bristol-Myers Squibb shares in Q2 2026, an estimated $77.9K.
Bristol-Myers Squibb made up 0.7% of Cypress Capital's portfolio in Q2 2026, its #31 holding.
Cypress Capital first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 30 quarters since.
Cypress Capital's Bristol-Myers Squibb position peaked at $2.93M in Q1 2025.
498 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Cypress Capital's 13F filing for Q2 2026, filed 17 Jul 2026.